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Abstract   
 
Background:  Dabigatran is an oral direct thrombin inhibitor approved by the US FDA for the 
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 
Dabigatran is rapidly replacing traditional anticoagulants, such as warfarin, despite the fact that 
clinicians have very little experience with dabigatran induced bleeding and no reliable therapeutic 
agent to reverse its effects. Prothrombin complex concentrate is effective at reversing traditional 
anticoagulants as it contains clotting factors, including prothrombin, the precursor to thrombin. 
How effective is prothrombin complex concentrate in reversing the anticoagulant activity of 
dabigatran? 
Method:  An exhaustive literature search using Medline/OVID, CINAHL, and Web of Science 
was performed using the search terms “dabigatran” and “prothrombin complex concentrate.” The 
search was limited to human studies. All studies were assessed for quality using the GRADE 
criteria. 
 
Results: There were 58 results were retrieved from the initial search with only two studies 
meeting the inclusion criteria. Both studies used coagulation assays as surrogate markers for 
reversal of dabigatran. A randomized, placebo-controlled, crossover study published in the 
Netherlands in 2011 studied in vivo the effects of the PCC Cofact® on the reversal of dabigatran 
in healthy male subjects. Cofact was found to have no effect on coagulation assays considered 
sensitive to dabigatran.  A randomized, crossover, ex vivo study published in France in 2012 
studied in vitro the effects of two PCCs, Kanokad® and FEIBA®, at varying doses on the 
reversal of dabigatran in healthy male subjects. Kanokad was shown to increase the amount of 
thrombin generated but only FEIBA corrected kinetic parameters modified by dabigatran. 
 
Conclusion:  The data available on the efficacy of PCC in reversing dabigatran is limited and 
mixed. Differing concentrations of PCC on the market and a lack of clear guidelines regarding 
dosage amounts further confounds the issue. At least one PCC, Cofact, has been proven 
ineffective at the studied dose in reversing dabigatran based on coagulation assays. While 
Kanokad has been shown to increase total thrombin production, only low-dose FEIBA has been 
proven to affect the kinetic parameters of thrombin generation modified by dabigatran without 
increased thrombotic risk, suggesting its potential success in clinical use. Further in vivo studies 
in human subjects are needed to validate the efficacy of FEIBA in reversing dabigatran. 
Keywords:  anticoagulant, Cofact, dabigatran, direct thrombin inhibitor, FEIBA, Kanokad, 
Pradaxa, prothrombin complex concentrate 
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The Effectiveness of Prothrombin Complex Concentrate in Reversing the 
Anticoagulant Activity of the Oral Direct Thrombin Inhibitor Dabigatran 
(Pradaxa®): A Review of Human Studies 
BACKGROUND 
Dabigatran (Pradaxa®) is an oral director thrombin inhibitor that was approved by 
the US FDA in 2010 for the prevention of stroke and systemic embolism in patients with 
nonvalvular atrial fibrillation. 1 For over 50 years, the vitamin K antagonist (VKA), 
warfarin, has been the mainstay of therapy for both short and long-term anticoagulation 
needs. 2 Disadvantages of warfarin therapy, such as the need for regular coagulation 
monitoring and various interactions with food and other drugs, 3 prompted research into 
the development of new drugs with more favorable treatment regimes. In February of 
2011, the American College of Cardiology and the American Heart Association made a 
class I recommendation4 for the use of dabigatran as an alternative to warfarin, despite 
the fact that clinicians have very little experience with dabigatran-induced bleeding and 
no reliable therapeutic agent to reverse its effects.1 
The results of two large trials provided practitioners with effective alternatives to 
warfarin therapy. In the RE-LY trial, 5 dabigatran was found to be more effective than 
warfarin in the prevention of stroke or systemic embolism in patients with nonvalvular 
atrial fibrillation. The RE-COVER trial6 found dabigatran to be noninferior to warfarin 
for the treatment of acute venous thromboembolism (VTE), prompting approval of its use 
for VTE prophylaxis in Europe. While these trials provided new options for providers, 
they also raised a significant clinical question—how is the potent anticoagulant activity 
of this new drug reversed? 
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Although dabigatran-associated bleeding events are considered rare, 7 significant 
safety concerns surround its use. In 2011, dabigatran accounted for 3781 adverse events, 
including 542 deaths (out of 30 385 total deaths reported to the FDA), 2367 reports of 
hemorrhage, 291 cases of acute renal failure, and 644 cases of stroke. Additionally, it was 
suspected in 15 cases of liver failure. In comparison, warfarin accounted for 1106 adverse 
events, including 72 deaths.2 
Prothrombin Complex Concentrate 
Traditional anticoagulants, such as warfarin, can be effectively reversed with the 
administration of Fresh Frozen Plasma (FFP) in conjunction with vitamin K, or isolated 
therapy with 4-factor prothrombin complex concentrate (PCC). The American College of 
Chest Physicians recently changed their guidelines for the management of reversing 
VKAs in favor of 4-factor PCC over FFP and vitamin K. However, these are Grade 2C 
recommendations, meaning there is uncertainty in the risk or benefits and benefits must 
be carefully balanced with risks. 8  
Prothrombin complex concentrate is effective in reversing warfarin coagulopathy 
as it replenishes the vitamin K-dependent clotting factors (II, VII, IX, and X), but these 
effects occur upstream from the site of activity of dabigatran in the clotting cascade.1 
Prothrombin complex concentrate is available in either 3-factor concentrate (contains 
clotting factors II, IX, and X) or 4-factor concentrate (contains clotting factors II, VII, IX, 
and X). 4-factor PCC is also available in either activated (FEIBA®) or nonactivated 
(Cofact®) formulations, but the nonactivated form is not currently available in the US. 
Both forms of PCC contain small amounts of endogenous anticoagulant proteins C and S, 
and both are associated with an increased risk of thrombotic events.8 
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Speculation as to the potential efficacy of PCC in the reversal of dabigatran is 
based on the fact that it contains clotting factors that ultimately lead to the production of 
factor II, or prothrombin, the precursor to thrombin. Some forms of PCC, such as 4-factor 
PCC, may also contain an activated form of factor VII (FVIIa), a vital clotting factor in 
initiating the clotting cascade. 9 To illustrate why the theory of PCC efficacy in 
dabigatran reversal is plausible, a brief review of the clotting cascade and dabigatran’s 
site of action are warranted.  
The Clotting Cascade 
When endothelial injury, or injury to the lining of a blood vessel, occurs a 
substance called tissue factor (TF) is released into the bloodstream. Primary hemostasis 
occurs at the site of the injury by the aggregation of platelets. Secondary hemostasis 
occurs simultaneously in the bloodstream by the activation of coagulation factors. In the 
bloodstream, TF comes into contact with activated factor VII, one of many 
procoagulants, or clotting factors, produced by the healthy liver. The coupling of TF and 
factor VII in the bloodstream triggers a complex chain reaction known as the clotting 
cascade, ultimately resulting in the formation of a fibrin clot. 1, 10  
The clotting cascade itself is divided into 2 pathways, intrinsic and extrinsic, that 
converge in a final common pathway.10 A simplified version of the clotting cascade 
demonstrates the site of activity of dabigatran (Figure I).1 Dabigatran directly inhibits the 
production of thrombin, a serine protease that is essential to clot formation. Thrombin has 
several functions, including: catalyzing the conversion of fibrinogen to fibrin, forming a 
fibrin clot; activation of additional clotting factors responsible for producing more 
thrombin; initiating platelet aggregation by activating their surface receptors; and 
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activation of factor XIII, which helps strengthen fibrin bonds in a formed clot. The direct 
thrombin inhibitors are unique, in that they can inactivate not only free thrombin in the 
bloodstream, but thrombin already bound to fibrin in a blood clot. 11  
The fact that no effective antidote exists has raised numerous concerns in the 
medical community with regard to the potentially devastating outcomes of closed-space 
bleeding, such as intracranial, pericardial, or spinal. 1 A recent article in the New York 
Times12 outlined the concerns of a Houston-based trauma physician, Dr. Bryan A. 
Cotton, who shared the story of a 70 year-old man taking dabigatran who fell at home, 
arrived to the emergency room alert and oriented, but subsequently bled to death on the 
table despite numerous interventions. Concerns of this sort are echoed elsewhere in the 
medical community via case reports13, 14 of difficulty in reversing dabigatran-induced 
bleeding, including two incidents of gastrointestinal bleeding in patients taking 
dabigatran that were not successfully stopped with the administration of PCC. One of the 
patients in the aforementioned cases14 died of multi-organ failure despite administration 
of PCC and FFP, although he did have significant medical comorbidities.  
The purpose of this review was to determine the efficacy of PCC in reversing the 
anticoagulant activity of dabigatran in human subjects. 
METHODS 
An exhaustive literature search using Medline/OVID, CINAHL, and Web of 
Science was performed using the search terms “dabigatran” and “prothrombin complex 
concentrate.” The search was limited to human studies. All studies were assessed for 
quality using the GRADE criteria.15 
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RESULTS 
Fifty-eight results were retrieved from the initial search with only two studies 
meeting the inclusion criteria: one randomized, placebo-controlled, crossover study16 and 
one randomized, crossover, ex vivo study. 17  
Netherlands study 
This randomized, placebo-controlled, crossover study16 in healthy subjects used 
the coagulation assays aPTT (actived partial thromboplastin time), ETP (endogenous 
thrombin potential lag time), TT (thrombin time) and ECT (ecarin clotting time) as 
surrogate markers for reversal of dabigatran and the direct factor Xa inhibitor, 
rivoroxaban.  Cofact (Sanquin Blood Supply, Amsterdam, the Netherlands), a 
nonactivated 4-factor PCC derived from human plasma, was the chosen PCC.16 
Twelve healthy males of unknown age without any relevant medical history were 
included in this study. All subjects had normal blood counts and normal kidney and liver 
function. Additionally, all subjects tested negative for hepatitis B, C and HIV.16 
Subjects were randomized to receive either dabigatran 150mg twice daily or 
rivaroxaban 20 mg twice daily for 2½ days, with the last dose being given on the third 
day with no food consumption. On the third day, subjects were admitted to the hospital 
for infusion of either 50U/kg PCC or a similar volume of saline as placebo. Blood was 
then collected for 24 hours after the infusion. After a washout period of 11 days, the 
subjects received treatment with the other anticoagulant drug following the same 
protocol.16 
Following administration of dabigatran, aPTT was increased from 33.6±3.3 to 
59.4±15.8 seconds. Neither PCC nor placebo (saline) had an effect on aPTT, with times 
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for PCC at 70.3±15.1 seconds; P=0.21 and saline at 57.9±10.3 seconds; P=0.64. No 
significant difference was found in aPTT between PCC and placebo (P=0.13). aPTT 
normalized within 24 hours.16 
Following administration of dabigatran, ETP lag time was prolonged from 
2.9±0.4 to 7.5±2.5 minutes (mean±SD; P<0.001). Neither PCC nor saline had an effect 
on ETP lag time prolongation, with PCC times of 8.7±2.6 minutes; P=0.20 and saline 
times of 8.5±2.2 minutes; P=0.22.16 
Following administration of dabigatran, TT increased to >120 seconds, the upper 
limit, for all subjects. TT remained immeasurable after infusion of both PCC and placebo 
for beyond 6 hours (P=0.36; repeated measures ANOVA).16 
Administration of dabigatran prolonged the ECT from 33.1±1 seconds at baseline 
to 69±26 seconds after 3 days of dabigatran intake (P=0.002). PCC did not reverse the 
prolongation of ECT but slightly increased it to 86±20 seconds (P=0.08). The same 
pattern of increased ECT was observed with placebo (mean±SD, P=0.08; repeated 
measures ANOVA). 16  
The authors concluded that Cofact was not effective in reversing the anticoagulant 
activity of dabigatran based on irreversible prolongation of the aPTT, ETP lag time, TT, 
and ECT in all subjects.16 
French study 
This randomized, crossover, ex-vivo study17 in healthy volunteers used TGT 
(thrombin generation test) parameters (Figure II) 18 as surrogate markers for reversal of 
dabigatran and the direct factor Xa inhibitor, rivaroxaban. Quantitative parameters were 
ETP-AUC (endogenous thrombin potential, area under the curve) and maximum 
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thrombin concentration (peak). Kinetic parameters were lag time (LT) and time to reach 
maximum thrombin concentration (TTP). Kanokad® (LFB, Courtabouef, France), a 4-
factor PCC, and activated prothrombin complex concentrate (FEIBA, Baxter AG, 
Vienna, Austria), were studied in comparison to recombinant activated factor VIIa 
(rFVIIa, Novoseven®, NovoNordisk, Copenhagen, Denmark). Data for rFVIIa will not 
be reported in this review.17 
Ten healthy white male subjects (age 18-45) with a body mass index between 18 
and 30kg/m2 were included in this study. Subjects with a personal or family history of 
thrombosis or bleeding disorders were excluded, as were those with renal or liver 
impairment.17 
Subjects were randomized to receive either dabigatran 150mg or rivaroxaban 
20mg in one oral dose. No information as given on randomization procedure. Venous 
blood samples were obtained just before drug administration and 2 hours after 
administration. The same process was repeated with the other anticoagulant drug after a 
15-day washout period. All assays were performed ex vivo.17 
Since no recommendations existed regarding dosage, each hemostatic agent was 
tested at 3 different concentrations. Kanokad was given at 0.25, 0.5, and 1U/mL; FEIBA 
at 0.25, 0.5, 1 and 2U/mL.17 
Thrombin generation test parameters were measured at baseline (H0) and 2 hours 
(H2) after oral intake of 150mg dabigatran. ETP at H0 was 1191(247) and decreased to 
953(182) at H2 (P=0.0013). Peak at H0 was 227.1(40.2) and decreased to 220.5(49.2) at 
H2 (P=0.5). LT at H0 was 2.15(0.31) and increased to 3.78(1.21) at H2 (P=0.0009). TTP 
was 4.23(0.62) at H0 and increased to 5.4(1.25) at H2 (P=0.002).17 
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Thrombin generation test parameters were measured again at H2 after 
administration of either Kanokad or FEIBA. Low doses of Kanokad or FEIBA decreased 
ETP-AUC close to baseline (approximately 1.5 and 1.6 nM.min, respectively) but higher 
doses caused a significant increase in thrombin generation (highest doses of Kanokad and 
FEIBA at 2.6 nM.min).17 
  In conclusion, the authors stated that PCCs, especially FEIBA, were reasonable 
choices for reversing the effects of dabigatran based on the ability of FEIBA at 0.5U/mL 
to reverse LT to near baseline despite overcorrection of ETP-AUC. The peak of thrombin 
generation remained below 400nM at the 0.5U/mL dose, with 500nM being the upper 
threshold for increased thrombotic risk. In light of this, the authors outlined the necessity 
for further defining the lowest effective dose of FEIBA.17 
 
DISCUSSION 
The question of whether or not PCC can effectively reverse the anticoagulant 
activity of dabigatran is of critical clinical importance, especially in the setting of major 
hemorrhage, closed-space bleeding, or the need for emergent surgical intervention. While 
animal studies7, 9 have pointed to the efficacy of PCC in reducing bleeding in rabbits and 
mice, these results cannot reliably be extrapolated to humans. Both studies included in 
this review aimed to test the effects of hemostatic agents on the anticoagulant activity of 
dabigatran in humans, and their authors note the necessity for further clinical studies. 
The studies were assessed using the Grading of Recommendations, Assessment, 
Development and Evaluation, or GRADE,15 criteria. The included studies were 
downgraded to a very low level of quality of evidence for limitations, such as small 
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sample size, all-male patient population, inclusion of only healthy patients, limited data 
in terms of patient demographics, and use of surrogate markers (blood tests). See Table I. 
Additionally, the French study17 used in vitro vs. in vivo testing methods. No evidence of 
publication bias or crossover effect was evident in either study. 
Concerns regarding the use of typical coagulation assays, and the use of other 
tests not readily available to practicing clinicians, have been brought to light. Traditional 
clotting assays, such as the aPTT, provide only qualitative information and do not 
adequately reflect the degree of anticoagulation, thereby raising the question of whether 
or not such tests can be used as markers of effective reversal.1 An earlier animal study19 
also questioned the correlation between aPTT and dabigatran reversal, pointing out that 
aPTT times remained immeasurable after administration of PCC while bleeding times 
were reduced, a finding that suggests aPTT may not be a reliable indicator of dabigatran 
reversal. The ECT, which uses snake venom, is considered the clotting test most sensitive 
to dabigatran and yet is not readily available to most clinicians.20 A cheaper, less-
sensitive version of the ECT, the Hemoclot® thrombin inhibitor assay, is also not readily 
available to many clinicians. 
Further studies in human subjects are necessary to determine the true efficacy of 
PCC in reversing dabigatran. A larger patient population, as well as one more 
representative of those actually taking the drug for therapy, would yield more meaningful 
results. The effects of PCC on coagulation of most interest to clinicians would be in the 
setting of acute hemorrhage, especially closed-space bleeding. However, constructing 
such trials in humans would be challenging given the relatively rare occurrence of 
bleeding events. At this point, a reasonable course of action might be to provide major 
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trauma centers with a PCC shown to have some benefit, such as FEIBA, and to study its 
efficacy in the patient suffering from dabigatran-induced hemorrhage in conjunction with 
providing standard resuscitation. Additionally, some physicians have suggested the 
creation of a national or international registry to monitor bleeding events and their 
treatment.21 
To date, the only recommended options for the general treatment of dabigatran 
induced bleeding are outlined in recommendations published in 2009 for patients taking 
novel anticoagulant drugs who present with bleeding. Treatment involves supportive care 
with fluid resuscitation; red blood cell transfusion; diagnostic or therapeutic interventions 
aimed at identifying the source of bleeding; and application of local hemostatic measures 
if the site of bleeding is accessible.22  
Additionally, reversal can be treated with measures used in the setting of a typical 
drug overdose, such as emergent hemodialysis or hemoperfusion, gastric lavage or 
administration of activated charcoal if the drug has been taking within a few hours. The 
aforementioned interventions have significant limitations, however, such as the 
availability of emergent hemodialysis or hemoperfusion and obtaining vascular access in 
the anticoagulated patient.8  
 
CONCLUSION 
Ultimately, the data available on the efficacy of PCC in reversing dabigatran is 
limited and mixed. Differing concentrations of PCC on the market and a lack of clear 
guidelines regarding dosage amounts further confounds the issue. At least one PCC, 
Cofact, has been proven ineffective at the studied dose in reversing the anticoagulant 
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activity of the oral direct thrombin inhibitor dabigatran in human subjects based on 
coagulation assays. While Kanokad has been shown to increase total thrombin 
production, only low-dose FEIBA has been proven to affect the kinetic parameters of 
thrombin generation modified by dabigatran without increased thrombotic risk, 
suggesting its potential success in clinical use. Further in vivo studies in human subjects 
are needed to validate the efficacy of FEIBA in reversing dabigatran.  
These facts raise significant clinical and ethical considerations when considering 
dabigatran for treatment. The fact that no antidote has been proven in humans begs the 
question of whether or not providers should be prescribing the drug so liberally. While it 
is assumed that providers fully disclose the associated risks and benefits of a specific 
drug therapy to patients, too often this is not the case. These studies outline the critical 
importance of choosing the right drug for the right patient, and carefully weighing 
increased benefits with associated risks.  
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TABLE 1  Characteristics of Reviewed Studies, GRADE profile 
 
  
a Netherlands study used dabigatran 150 mg, 2 times daily dosing with measurements taken after 2½ days 
French study used measurements taken at baseline and 2 hours after administration of dabigatran 150mg 
b  Netherlands study used Cofact 50U/kg 
c French study used Kanokad at 3 concentration: 0.25U/mL, 0.5U/mL and 1U/mL and FEIBA at 4 concentrations: 0.25U/mL, 0.5U/mL, 1U/mL, and 2U, mL 
d Netherlands study was downgraded for small sample size; French study was downgraded for small sample sample size and use of in vitro testing methods 
 
1 H0 = baseline measurement at hour zero 
2 H2 = measurement 2 hours after administration of dabigatran 150mg 
3 TTP data was not given as TTP was found to correlate strongly with LT 
 
Values in ORANGE are estimated from bar graphs on p 1577 of Netherlands study and p 222 of French study. Data are expressed as mean relative change from H2 ± SD. 
 
 
 
 
 
Quality Assessment Summary of Findings 
Importance Downgrade criteria 
Design Methodology Indirectness Imprecision Inconsistency 
Publication bias 
likely 
Quality Study 
Treatment 
(total) 
Value before 
dabigatran  
Value after 
dabigatran 
150mga 
Value after PCC 
Netherlands (in vivo) study16  
Randomized 
Placebo 
Controlled 
Crossover 
Study 
No serious 
limitations 
No serious 
limitations 
Serious 
limitationsd 
No serious 
limitations 
No serious 
limitations 
Very low 
aPTT 6 
33.6 +/- 3.3 
seconds 
59.4 +/- 15.8 
seconds 
Cofactb 
Less important 
No effect 
ETP lag time 6 
2.9 +/- 0.4 
minutes 
7.5 +/- 2.5 
minutes 
No effect Critical 
TT 6 20 seconds > 120 seconds > 120 seconds Important 
ECT 6 
33 +/- 1 
seconds 
69 +/- 26 
seconds 
86 +/- 20 seconds Critical 
French (ex vivo)17   
Randomized 
Controlled 
Crossover 
Ex-vivo 
Study 
No serious 
limitations 
Serious 
limitationsd 
Serious 
limitationsd 
No serious 
limitations 
No serious 
limitations 
Very low 
ETP-AUC 5 
H01: 1191 
(247) 
nM.min 
H22: 953 (182) 
nM.min 
Kanokadc FEIBAc 
Important 
1.50 1.60 
1.90 1.80 
2.60 2.40 
 2.60 
Peak 5 
H0: 227.1 
(40.2) 
nM 
H2: 220.5 
(49.2) 
nM 
296.2±57.3 361±28 
Critical 
Data not given  Data not given 
462.1±81.9 Data not given 
 551.7±99.5 
LT 5 
H0: 2.16 (0.31) 
seconds 
H2: 3.78 (1.21) 
seconds 
0.90 0.80 
Important 
0.89 0.71 
0.89 0.70 
 0.70 
TTP3 5 
H0: 4.23 (0.62) 
seconds 
H2: 5.4 (1.25) 
seconds 
Data not given 
4.85±0.52 
Important 
Data not given 
Data not given 
Data not given 
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Figure I: Clotting cascade and site of activity of dabigatran1 
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Figure II: Thrombin Generation Test (TGT) parameters18 
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